Press Releases

Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
September 10, 2024
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
September 3, 2024
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
August 8, 2024
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
July 29, 2024
Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
July 23, 2024
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
July 12, 2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 8, 2024
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
July 1, 2024
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
May 24, 2024